Senores Pharmaceuticals Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Senores Pharmaceuticals Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Senores Pharmaceuticals shares trading at Rs.1,382 against a market capitalisation of Rs.6,356 Cr and a price-to-earnings multiple of 52.3. As a pharmaceuticals and life sciences name on the NSE and BSE, Senores Pharmaceuticals enters the Senores Pharmaceuticals Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Senores Pharmaceuticals Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.141 Cr revenue and Rs.21 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Senores Pharmaceuticals Research at Univest

About Senores Pharmaceuticals

Senores Pharmaceuticals (NSE: SENORES) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Senores Pharmaceuticals Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.193 Cr and net profit of Rs.37 Cr, forming the base against which the Senores Pharmaceuticals Q1 Results FY27 estimates in this article are built. This Senores Pharmaceuticals Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Senores Pharmaceuticals Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	197-227	141	+50.0%
Net Profit / PAT (Rs. Cr)	28-36	21	+50.0%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.1,658-1,838

Univest, a SEBI-Registered Investment Advisor, Tracks Senores Pharmaceuticals Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Senores Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Senores Pharmaceuticals share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Senores Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Senores Pharmaceuticals share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Senores Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Senores Pharmaceuticals share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Senores Pharmaceuticals’s live price and Q1 FY27 result updates.

Key Risks to the Senores Pharmaceuticals Q1 Results FY27 Outlook

• Pricing pressure in key export markets, particularly the US generics segment.
• Regulatory or plant compliance issues affecting supply continuity.
• R&D and capacity expansion costs weighing on near-term profitability.

Q4 FY26 Performance Context for the Senores Pharmaceuticals Q1 Results FY27 Print

Senores Pharmaceuticals closed Q4 FY26 with revenue of Rs.193 Cr and net profit of Rs.37 Cr, a year-on-year revenue change of +53.1% and PAT change of +104.1% versus Q4 FY25. This base underpins the Senores Pharmaceuticals Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Senores Pharmaceuticals Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Senores Pharmaceuticals Q1 Results FY27

Senores Pharmaceuticals shares last traded at Rs.1,382. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Senores Pharmaceuticals Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Senores Pharmaceuticals Q1 Results FY27 trailing-growth framework points to a range of Rs.1,448-1,558 for Senores Pharmaceuticals, contingent on the Senores Pharmaceuticals Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Senores Pharmaceuticals Q1 Results FY27 view for Senores Pharmaceuticals works out to Rs.1,658-1,838, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Senores Pharmaceuticals Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Senores Pharmaceuticals Q1 Results FY27 analysis would put Senores Pharmaceuticals in a Rs.1,893-2,142 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Senores Pharmaceuticals Q1 Results FY27 Print

• Revenue and PAT versus the Senores Pharmaceuticals Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Senores Pharmaceuticals Q1 Results FY27 narrative.
• Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
• Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Senores Pharmaceuticals Q1 Results FY27

Senores Pharmaceuticals enters the Q1 FY27 results season trading at Rs.1,382, with the 12-month Uniresearch target range of Rs.1,658-1,838 reflecting a tracking with a constructive bias stance. Investors tracking the Senores Pharmaceuticals Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Senores Pharmaceuticals Q1 Results FY27

When are Senores Pharmaceuticals Q1 FY27 results expected?

Ans. Senores Pharmaceuticals’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Senores Pharmaceuticals Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Senores Pharmaceuticals’s Q1 FY27 revenue is Rs.197-227 Cr, based on the Q1 FY26 base of Rs.141 Cr.

What is the Senores Pharmaceuticals share price target?

Ans. The 12-month Uniresearch estimate for Senores Pharmaceuticals share price target is Rs.1,658-1,838, based on trailing growth and current valuation multiples.

Is Senores Pharmaceuticals a good buy before Q1 FY27 results?

Ans. Senores Pharmaceuticals is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Senores Pharmaceuticals’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Senores Pharmaceuticals share price live?

Ans. Senores Pharmaceuticals share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.